Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Bevacizumab in Diabetic Macular Edema
NCT07338097Enrolling by invitation
- Sponsor
- CMH Multan Institute of Medical Sciences
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by CMH Multan Institute of Medical Sciences. Primary endpoint: Mean Change in Visual Acuity Letter Score at 2 months. Started Sep 2025; status: enrolling by invitation.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07338097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07338097.